Display Settings:

Format
Sort by

Send to:

Choose Destination

Results: 3

1.

Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy.

Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA.

Pancreas. 2008 Oct;37(3):269-74. doi: 10.1097/MPA.0b013e31816d8185.

PMID:
18815548
[PubMed - indexed for MEDLINE]
2.

Metastatic pancreatic cancer response to treatment with cetuximab and gemcitabine plus capecitabine: a case report and review of the literature.

Li M, Jiang M, Yan X, Wang F, Luo F.

Tumori. 2010 Sep-Oct;96(5):764-7. Review.

PMID:
21302625
[PubMed - indexed for MEDLINE]
3.

[Prognostic significance of CA19-9 levels in patients with pancreatic cancer].

Shiozawa S, Tsuchiya A, Kim DH, Ogawa K.

Nihon Rinsho. 2006 Jan;64 Suppl 1:297-300. Review. Japanese. No abstract available.

PMID:
16457270
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk